Breaking News Instant updates and real-time market news.

2021-04-08 10:23:56 ORBC Taken private $11.51 / +3.925 (+51.78%) 10:23 04/08/21 04/08 10:23 04/08/21 10:23	Orbcomm downgraded to Hold from Buy at Craig-Hallum Craig-Hallum analyst Anthony Stoss downgraded Orbcomm to Hold from Buy with a $11.50 price target after the company announced an agreement to be acquired by GI Partners for $11.50 per share in cash.	21 Apr

2021-04-08 10:23:56

ORBC

Taken private

$11.51 / +3.925 (+51.78%)

10:23

04/08/21

04/08

10:23

04/08/21

10:23

Orbcomm downgraded to Hold from Buy at Craig-Hallum

Craig-Hallum analyst Anthony Stoss downgraded Orbcomm to Hold from Buy with a $11.50 price target after the company announced an agreement to be acquired by GI Partners for $11.50 per share in cash.

21
Apr

OTHER BREAKING NEWS FROM THE FLY

Recommendations	Paramount price target lowered to $44 from $47 at Citi » 06:26 05/23/22 05/23 06:26 05/23/22 06:26 PARA Paramount $32.66 / +0.43 (+1.33%) Citi analyst Jason… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PARA Paramount $32.66 / +0.43 (+1.33%) 05/16/22 Berkshire Hathaway adds Citi, exits Wells Fargo in Q1 05/05/22 Paramount CEO says doesn't need M&A to add scale, will always look at options 05/03/22 Paramount says Paramount+ will launch in India via joint venture in 2023 04/19/22 Roku drops 6% to $109.96 after Netflix losses subscribers in Q1 PARA Paramount $32.66 / +0.43 (+1.33%) 05/04/22 Deutsche Bank Paramount price target lowered to $43 from $45 at Deutsche Bank 04/19/22 Rosenblatt Paramount initiated with a Sell at Rosenblatt 04/14/22 Deutsche Bank Paramount price target raised to $45 from $43 at Deutsche Bank 04/01/22 JPMorgan Paramount reinstated with a Neutral at JPMorgan PARA Paramount $32.66 / +0.43 (+1.33%) 05/03/22 Paramount reports Q1 EPS 60c, consensus 51c 05/02/22 Notable companies reporting before tomorrow's open 05/02/22 Notable companies reporting before tomorrow's open PARA Paramount $32.66 / +0.43 (+1.33%) 05/06/22 CBS CEO tries to boost moral after 'well-being survey' results, NY Post reports 04/04/22 'Sonic 2' film amasses $25.5M internationally, Gamesindustry.biz says 03/30/22 Hulu loses Paramount, MGM films as EPIX deal ends, The Streamable says 02/28/22 Discovery plans to name Chris Licht to lead CNN, WSJ reports PARA Paramount $32.66 / +0.43 (+1.33%) 05/22/22 Box Office Battle: 'Doctor Strange 2' wins weekend with another $31.6M 05/17/22 What You Missed On Wall Street On Tuesday 05/17/22 What You Missed On Wall Street This Morning 05/15/22 Box Office Battle: 'Doctor Strange 2' wins weekend with another $61M 00:00 Today 50th Annual Global Technology, Media & Communications Conference 05/25/22 Paramount - PARA 06/08/22 Paramount Global PARA Paramount $32.66 / +0.43 (+1.33%) 05/18/22 Paramount Global call volume above normal and directionally bullish 05/17/22 Early notable gainers among liquid option names on May 17th 05/17/22 Unusually active option classes on open May 17th 05/09/22 Paramount Global call volume above normal and directionally bullish
Initiation	Horizon Therapeutics initiated with a Market Perform at SVB Leerink » 06:26 05/23/22 05/23 06:26 05/23/22 06:26 HZNP Horizon Therapeutics $90.33 / +0.96 (+1.07%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events HZNP Horizon Therapeutics $90.33 / +0.96 (+1.07%) 05/17/22 Horizon Therapeutics enrolls first patient in daxdilimab trial 05/16/22 Paulson exits Cerner, boosts Didi in Q1 05/11/22 Horizon Therapeutics launches letter-writing campaign for Thyroid Eye Disease 05/03/22 Horizon Therapeutics announces dazodalibep trial meets primary endpoint HZNP Horizon Therapeutics $90.33 / +0.96 (+1.07%) 03/14/22 Oppenheimer Horizon Therapeutics initiated with an Outperform at Oppenheimer 01/26/22 Piper Sandler Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler 01/18/22 JPMorgan Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan 12/08/21 Fly Intel: Top five analyst initiations HZNP Horizon Therapeutics $90.33 / +0.96 (+1.07%) 05/04/22 Horizon Therapeutics reports Q1 EPS $1.34, consensus $1.14 03/01/22 Horizon Therapeutics sees FY22 revenue $3.9B-$4B, consensus $3.91B 03/01/22 Horizon Therapeutics reports Q4 EPS $1.41, consensus $1.34 HZNP Horizon Therapeutics $90.33 / +0.96 (+1.07%) 03/01/22 Fly Intel: Pre-market Movers 07/07/22 PDUFA Date for KRYSTEXXA
Upgrade	Consolidated Edison upgraded to Neutral from Sell at Guggenheim » 06:26 05/23/22 05/23 06:26 05/23/22 06:26 ED Consolidated Edison $95.81 / +0.905 (+0.95%) Guggenheim analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate ED Consolidated Edison $95.81 / +0.905 (+0.95%) 01/20/22 Consolidated Edison raises annual dividend to $3.16 from $3.10 per share 12/30/21 W.Va regulators issue water quality certification for Mountain Valley Pipeline ED Consolidated Edison $95.81 / +0.905 (+0.95%) 05/03/22 Wells Fargo Wells Fargo downgrades Consolidated Edison to sell on 'tricky' NY rate case 05/02/22 Wells Fargo Consolidated Edison downgraded to Underweight from Equal Weight at Wells Fargo 04/25/22 Credit Suisse Consolidated Edison initiated with a Neutral at Credit Suisse 03/10/22 Mizuho Consolidated Edison price target raised to $94 from $90 at Mizuho ED Consolidated Edison $95.81 / +0.905 (+0.95%) 05/05/22 Consolidated Edison backs FY22 EPS view of $4.40-$4.60, consensus $4.49 05/05/22 Consolidated Edison reports Q1 EPS $1.47, consensus $1.48 02/17/22 Consolidated Edison reports Q4 operating revenue $3.42B, consensus $2.76B 02/17/22 Consolidated Edison sees FY22 adjusted EPS $4.40-$4.60, consensus $4.48 16 Jun
Recommendations	Dell Technologies price target lowered to $65 from $70 at Citi » 06:25 05/23/22 05/23 06:25 05/23/22 06:25 DELL Dell Technologies $40.05 / -1 (-2.44%) Citi analyst Jim Suva… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options DELL Dell Technologies $40.05 / -1 (-2.44%) 05/22/22 Fly Intel: Top five weekend stock stories 05/16/22 Elliott adds Diamond Offshore, exits Arconic in Q1 05/12/22 Arrow Electronics appoints Kirk Schell as president, global components 02/24/22 Dell Technologies initiates quarterly dividend of 33c per share DELL Dell Technologies $40.05 / -1 (-2.44%) 04/19/22 KGI Securities Dell Technologies initiated with a Neutral at KGI Securities 04/01/22 Goldman Sachs Dell Technologies downgraded to Neutral from Conviction Buy at Goldman Sachs 03/31/22 Barclays Dell Technologies price target lowered to $53 from $54 at Barclays 03/31/22 Morgan Stanley Dell Technologies downgraded to Equal Weight from Overweight at Morgan Stanley DELL Dell Technologies $40.05 / -1 (-2.44%) 02/24/22 Dell Technologies reports Q4 adjusted EPS $1.72, consensus $1.95 02/24/22 Notable companies reporting after market close 11/23/21 Dell Technologies reports Q3 adjusted EPS $2.37, consensus $2.18 11/23/21 Notable companies reporting after market close DELL Dell Technologies $40.05 / -1 (-2.44%) 05/22/22 Broadcom in talks to acquire VMware, Reuters reports 01/01/22 Amazon looks particularly attractive after wild year for tech, Barron's says DELL Dell Technologies $40.05 / -1 (-2.44%) 04/04/22 Fly Insider: TMC the Metals, Dell among week's notable insider trades 04/01/22 What You Missed On Wall Street On Friday 04/01/22 What You Missed On Wall Street This Morning 04/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/26/22 Dell Technologies - DELL 06/27/22 Dell Technologies Inc. CL C DELL Dell Technologies $40.05 / -1 (-2.44%) 11/23/21 Dell Technologies options imply 4.8% move in share price post-earnings
Recommendations	Marvell price target lowered to $80 from $95 at UBS » 06:24 05/23/22 05/23 06:24 05/23/22 06:24 MRVL Marvell $54.13 / -0.18 (-0.33%) UBS analyst Timothy… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options MRVL Marvell $54.13 / -0.18 (-0.33%) 05/09/22 Marvell to acquire Tanzanite in an all-cash transaction 04/20/22 Marvell appoints Sara Andrews to board of directors 04/14/22 Worldwide semiconductor revenue grew 26% in 2021, Gartner says 03/14/22 Marvell CEO: The company is performing extremely well MRVL Marvell $54.13 / -0.18 (-0.33%) 05/20/22 Oppenheimer Marvell price target lowered to $90 from $110 at Oppenheimer 05/17/22 Piper Sandler Piper moves to 'more positive stance' on semiconductor stocks 04/25/22 Raymond James Marvell upgraded to Outperform from Market Perform at Raymond James 04/25/22 Raymond James Marvell upgraded to Outperform from Market Perform at Raymond James MRVL Marvell $54.13 / -0.18 (-0.33%) 03/03/22 Marvell sees Q1 adjusted EPS 51c +/- 3c, consensus 50c 03/03/22 Marvell reports Q4 adjusted EPS 50c, consensus 48c 03/03/22 Notable companies reporting after market close 12/02/21 Marvell sees Q4 adjusted EPS 48c +/- 3c, consensus 42c MRVL Marvell $54.13 / -0.18 (-0.33%) 03/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/03/22 Fly Intel: After-Hours Movers 12/03/21 Wall Street in Fives - Must Read Lists for Friday 12/03/21 Wall Street in Fives - Must Read Lists at Midday 05/26/22 Marvell - MRVL 06/23/22 Marvell Technology Inc MRVL Marvell $54.13 / -0.18 (-0.33%) 04/28/22 Unusually active option classes on open April 28th 04/07/22 Marvell call buyer realizes 23% same-day gains 04/06/22 Marvell call volume above normal and directionally bullish 12/09/21 Marvell call volume above normal and directionally bullish

Recommendations	Foot Locker price target raised to $32 from $30 » 06:24 05/23/22 05/23 06:24 05/23/22 06:24 FL Foot Locker $31.52 / +1.22 (+4.03%) Baird analyst Jonathan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options FL Foot Locker $31.52 / +1.22 (+4.03%) 05/20/22 Foot Locker rises 9.5% 05/20/22 Foot Locker sees FY22 comparable sales down 8%-10% 05/05/22 Foot Locker, Adidas announce new long-term strategic partnership 03/24/22 Foot Locker targets net zero GHG emissions by 2050 or sooner FL Foot Locker $31.52 / +1.22 (+4.03%) 05/16/22 Deutsche Bank Foot Locker price target lowered to $30 from $32 at Deutsche Bank 05/16/22 OTR Global Foot Locker downgraded to Mixed from Positive at OTR Global 03/28/22 Cowen Cowen cuts Foot Locker to Market Perform, more cautious following March data 03/28/22 Cowen Foot Locker downgraded to Market Perform from Outperform at Cowen FL Foot Locker $31.52 / +1.22 (+4.03%) 05/20/22 Foot Locker backs FY22 EPS $4.25-$4.60, consensus $4.41 05/20/22 Foot Locker reports Q1 EPS $1.60, consensus $1.55 05/19/22 Notable companies reporting before tomorrow's open 05/19/22 Notable companies reporting before tomorrow's open FL Foot Locker $31.52 / +1.22 (+4.03%) 03/05/22 Foot Locker has gotten hit hard, stock looks like a buy, Barron's says 03/02/22 Fanatics valued at $27B in latest fundraising, WSJ reports FL Foot Locker $31.52 / +1.22 (+4.03%) 05/20/22 What You Missed On Wall Street On Friday 05/20/22 What You Missed On Wall Street This Morning 05/20/22 Fly Intel: Pre-market Movers 03/28/22 What You Missed On Wall Street On Monday 05/24/22 6th Annual Future of the Consumer: Sustainable Growth for a New Ecosystem 08/19/22 Foot Locker - FL FL Foot Locker $31.52 / +1.22 (+4.03%) 05/20/22 Unusually active option classes on open May 20th 04/20/22 Foot Locker call volume above normal and directionally bullish 03/04/22 Foot Locker put volume heavy and directionally bearish 02/23/22 Unusually active option classes on open February 23rd
Initiation	AbbVie initiated with an Underperform at SVB Leerink » 06:23 05/23/22 05/23 06:23 05/23/22 06:23 ABBV AbbVie $151.04 / -0.8 (-0.53%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ABBV AbbVie $151.04 / -0.8 (-0.53%) 05:26 Today AbbVie receives CHMP recommendation for upadacitinib approval 05/20/22 AbbVie submits NDA to FDA for ABBV-951 05/16/22 Berkshire Hathaway adds Citi, exits Wells Fargo in Q1 05/16/22 AbbVie, Cugene announce collaboration in autoimmune diseases ABBV AbbVie $151.04 / -0.8 (-0.53%) 05/13/22 Piper Sandler Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler 05/06/22 Daiwa AbbVie downgraded to Neutral from Outperform at Daiwa 05/03/22 Morgan Stanley Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure 05/02/22 Morgan Stanley AbbVie's recent weakness a buying opportunity, says Morgan Stanley ABBV AbbVie $151.04 / -0.8 (-0.53%) 04/29/22 AbbVie sees FY22 revenue $59.4B, consensus $60.22B 04/29/22 AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50 04/29/22 AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20 04/29/22 AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14 ABBV AbbVie $151.04 / -0.8 (-0.53%) 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports ABBV AbbVie $151.04 / -0.8 (-0.53%) 05/10/22 What You Missed On Wall Street On Tuesday 05/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/29/22 What You Missed On Wall Street On Friday 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 09/07/22 2022 Wells Fargo Healthcare Conference ABBV AbbVie $151.04 / -0.8 (-0.53%) 04/29/22 Unusually active option classes on open April 29th 02/24/22 AbbVie put volume heavy and directionally bearish 01/24/22 AbbVie put volume heavy and directionally bearish 12/06/21 Unusually active option classes on open December 6th
Recommendations	Stealth Biotherapeutics price target lowered to $1.50 from $4 at H.C. Wainwright » 06:22 05/23/22 05/23 06:22 05/23/22 06:22 MITO Stealth Biotherapeutics / + H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research MITO Stealth Biotherapeutics / + 05/12/22 Stealth Biotherapeutics granted FDA orphan designation for elamipretide 05/10/22 Stealth Biotherapeutics granted FDA Orphan Designation for DMD treatment 05/02/22 Stealth BioTherapeutics Corporation (ADS) trading resumes 05/02/22 Stealth BioTherapeutics Corporation (ADS) trading halted, news pending MITO Stealth Biotherapeutics / + 07/01/21 Maxim Stealth Biotherapeutics initiated with a Buy at Maxim 07/01/21 Maxim Stealth Biotherapeutics initiated with a Buy at Maxim
Recommendations	Zymeworks price target lowered to $40 from $44 at H.C. Wainwright » 06:21 05/23/22 05/23 06:21 05/23/22 06:21 ZYME Zymeworks $5.99 / +0.155 (+2.66%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly ZYME Zymeworks $5.99 / +0.155 (+2.66%) 05/20/22 Zymeworks rejects unsolicited acquisition proposal from All Blue Falcons FZE 05/04/22 Zymeworks expects cash to fund operations into second half of 2023 04/29/22 Zymeworks rises 31.7% 04/29/22 Zymeworks rises 53.9% ZYME Zymeworks $5.99 / +0.155 (+2.66%) 05/09/22 Citi Zymeworks should reject 'opportunistic' $10.50 per share offer, says Citi 05/05/22 Guggenheim Zymeworks upgraded to Buy at Guggenheim amid low expectations 05/05/22 Guggenheim Zymeworks upgraded to Buy from Neutral at Guggenheim 03/15/22 Evercore ISI Zymeworks initiated with an Outperform at Evercore ISI ZYME Zymeworks $5.99 / +0.155 (+2.66%) 05/04/22 Zymeworks reports Q1 adjusted EPS ($1.17), consensus ($1.67) 02/24/22 Zymeworks reports Q4 EPS (95c), consensus ($1.14) 27 Jan ZYME Zymeworks $5.99 / +0.155 (+2.66%) 05/05/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/29/22 What You Missed On Wall Street On Friday 04/29/22 What You Missed On Wall Street This Morning 04/29/22 Fly Intel: Pre-market Movers
Recommendations	Atara Biotherapeutics price target lowered to $29 from $31 at H.C. Wainwright » 06:20 05/23/22 05/23 06:20 05/23/22 06:20 ATRA Atara Biotherapeutics $5.17 / +0.015 (+0.29%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ATRA Atara Biotherapeutics $5.17 / +0.015 (+0.29%) 05/19/22 Atara Biotherapeutics down 14% at $4.44 after announcing end of Bayer deal 05/19/22 Atara provides update on Bayer collaboration 05/05/22 Atara Bio sees cash, equivalents sufficient to fund operations into 4Q23 04/06/22 Applied Molecular Transport appoints Banard to board of directors ATRA Atara Biotherapeutics $5.17 / +0.015 (+0.29%) 05/09/22 Citi Citi downgrades Atara Biotherapeutics on lack of near-term drivers 05/09/22 Citi Atara Biotherapeutics downgraded to Neutral from Buy at Citi 03/28/22 JPMorgan Atara Biotherapeutics price target lowered to $22 from $27 at JPMorgan 03/08/22 Mizuho Atara Biotherapeutics price target lowered to $39 from $41 at Mizuho ATRA Atara Biotherapeutics $5.17 / +0.015 (+0.29%) 05/05/22 Atara Biotherapeutics reports Q1 EPS (87c), consensus (98c) 02/28/22 Atara Biotherapeutics reports Q4 EPS (96c), consensus (69c) 06/23/22 Atara Biotherapeutics, Inc.

Recommendations	Snowflake price target lowered to $180 from $260 at UBS » 06:20 05/23/22 05/23 06:20 05/23/22 06:20 SNOW Snowflake $141.51 / -5.36 (-3.65%) UBS analyst Karl… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNOW Snowflake $141.51 / -5.36 (-3.65%) 05/16/22 Lone Pine adds TSMC in Q1, exits KE Holdings and Adobe 05/16/22 Tiger Global buys Starry, exits Adobe in Q1 03/29/22 Snowflake extends relationship with AWS 03/06/22 Fly Intel: Top five weekend stock stories SNOW Snowflake $141.51 / -5.36 (-3.65%) 05/20/22 Barclays Snowflake price target lowered to $218 from $313 at Barclays 05/18/22 Mizuho Snowflake price target lowered to $225 from $370 at Mizuho 05/10/22 Truist Snowflake price target lowered to $300 from $350 at Truist 04/25/22 Wolfe Research Snowflake initiated with an Outperform at Wolfe Research SNOW Snowflake $141.51 / -5.36 (-3.65%) 03/02/22 Snowflake sees FY23 product revenue $1.88B-$1.9B 03/02/22 Snowflake reports Q4 EPS (43c), consensus 3c 03/02/22 Notable companies reporting after market close 12/01/21 Snowflake reports Q3 EPS (51c), consensus (6c) SNOW Snowflake $141.51 / -5.36 (-3.65%) 05/21/22 Some stocks that aren't as cheap as they look, Barron's says 03/05/22 Cloud stocks have become a haven in tech, Barron's says SNOW Snowflake $141.51 / -5.36 (-3.65%) 04/25/22 What You Missed On Wall Street On Monday 04/25/22 What You Missed On Wall Street This Morning 04/25/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/31/22 What You Missed On Wall Street On Thursday 05/26/22 Technology 05/25/22 Snowflake - SNOW SNOW Snowflake $141.51 / -5.36 (-3.65%) 05/20/22 Snowflake put volume heavy and directionally bearish 05/19/22 Snowflake call volume above normal and directionally bullish 04/29/22 Snowflake call volume above normal and directionally bullish 04/06/22 Snowflake put volume heavy and directionally bearish
Initiation	Amgen initiated with a Market Perform at SVB Leerink » 06:20 05/23/22 05/23 06:20 05/23/22 06:20 AMGN Amgen / + SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AMGN Amgen / + 05/16/22 Crispr Therapeutics appoints Morrow as CMO 05/04/22 BeiGene granted conditional approval of Blincyto by China NMPA 04/27/22 Amgen receives notice of deficiency from IRS for 2013-2015 period 04/27/22 Amgen's reports safety and efficacy results of Repatha Phase 3 studies AMGN Amgen / + 05/10/22 Mizuho Amgen price target raised to $208 from $202 at Mizuho 05/05/22 Stifel ASCO sets up as 'downside-biased' for Mirati investors, says Stifel 04/28/22 BMO Capital Amgen price target lowered to $243 from $263 at BMO Capital 04/28/22 Piper Sandler Amgen price target raised to $260 from $255 at Piper Sandler AMGN Amgen / + 04/27/22 Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.63 04/27/22 Amgen reports Q1 adjusted EPS $4.25, consensus $4.10 04/27/22 Notable companies reporting after market close 02/08/22 Amgen sees FY22 revenue $25.4B-$26.5B, consensus $27B AMGN Amgen / + 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports 12/14/21 Moderna, Amgen among biotech companies pulling out of JPM conference, STAT says AMGN Amgen / + 04/28/22 What You Missed On Wall Street On Thursday 04/27/22 Fly Intel: After-Hours Movers 02/08/22 Wall Street in Fives - Must Read Lists for Tuesday 02/08/22 Wall Street in Fives - Must Read Lists at Midday 06/03/22 2022 ASCO Annual Meeting 06/21/22 Amgen AMGN Amgen / + 02/08/22 Early notable gainers among liquid option names on February 8th 01/03/22 Amgen call volume above normal and directionally bullish
Recommendations	Angion Biomedica price target lowered to $28 from $32 at H.C. Wainwright » 06:20 05/23/22 05/23 06:20 05/23/22 06:20 ANGN Angion Biomedica $1.29 / +0.05 (+4.03%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research On The Fly Events ANGN Angion Biomedica $1.29 / +0.05 (+4.03%) 05/16/22 Angion Biomedica reports Q1 EPS (48c), consensus (43c) 12/29/21 Angion Biomedica CEO buys $730K in common stock 12/09/21 Angion Biomedica, Vifor Pharma announce GUARD trial misses primary endpoint ANGN Angion Biomedica $1.29 / +0.05 (+4.03%) 04/18/22 H.C. Wainwright Angion Biomedica price target lowered to $32 from $50 at H.C. Wainwright 12/10/21 Oppenheimer Angion Biomedica price target lowered to $8 from $15 at Oppenheimer 11/09/21 H.C. Wainwright Angion Biomedica price target lowered to $50 from $100 at H.C. Wainwright 10/27/21 Oppenheimer Angion Biomedica price target lowered to $15 from $38 at Oppenheimer ANGN Angion Biomedica $1.29 / +0.05 (+4.03%) 12/29/21 Fly Intel: After-Hours Movers 06/09/22 Angion Biomedica Corp.
Recommendations	Spero Therapeutics price target lowered to $10 from $37 at H.C. Wainwright » 06:20 05/23/22 05/23 06:20 05/23/22 06:20 SPRO Spero Therapeutics $1.37 / -0.065 (-4.53%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events SPRO Spero Therapeutics $1.37 / -0.065 (-4.53%) 05/03/22 Spero will immediately defer current commercialization activities for tebipenem 04/06/22 Spero Therapeutics publishes ADAPT-PO clinical trial data in NEJM 03/31/22 FDA notifies Spero of deficiencies in tebipenem NDA 02/16/22 Spero Therapeutics announces results from Phase 1 BAL trial of SPR206 SPRO Spero Therapeutics $1.37 / -0.065 (-4.53%) 05/20/22 Berenberg Spero Therapeutics downgraded to Hold from Buy at Berenberg 05/17/22 Cantor Fitzgerald Spero Therapeutics price target lowered to $5 from $27 at Cantor Fitzgerald 05/04/22 Cowen Spero Therapeutics downgraded to Market Perform from Outperform at Cowen 05/03/22 Evercore ISI Evercore downgrades Spero with $2 target after 'shocking update' SPRO Spero Therapeutics $1.37 / -0.065 (-4.53%) 05/16/22 Spero Therapeutics reports Q1 EPS ($1.01), consensus (87c) 03/31/22 Spero Therapeutics reports Q4 EPS (90c), consensus (75c) SPRO Spero Therapeutics $1.37 / -0.065 (-4.53%) 03/31/22 Fly Intel: After-Hours Movers 06/27/22 PDUFA Date for Tebipenem HBr Oral Tablets
Recommendations	BioXcel Therapeutics price target lowered to $110 from $134 at H.C. Wainwright » 06:19 05/23/22 05/23 06:19 05/23/22 06:19 BTAI BioXcel Therapeutics $13.61 / +0.355 (+2.68%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly BTAI BioXcel Therapeutics $13.61 / +0.355 (+2.68%) 05/20/22 BioXcel announces updated presentation time at HC Wainwright conference 05/09/22 BioXcel Therapeutics announces upcoming milestones 05/03/22 BioXcel Therapeutics announces first patient dosed in TRANQUILITY II study 04/19/22 BioXcel Therapeutics announces formation of OnkosXcel Therapeutics BTAI BioXcel Therapeutics $13.61 / +0.355 (+2.68%) 05/13/22 Canaccord BioXcel Therapeutics price target lowered to $75 from $84 at Canaccord 05/10/22 Truist BioXcel Therapeutics price target lowered to $71 from $125 at Truist 04/20/22 Canaccord BioXcel Therapeutics shares remain significantly undervalued, says Canaccord 04/14/22 H.C. Wainwright BioXcel Therapeutics price target raised to $134 from $130 at H.C. Wainwright BTAI BioXcel Therapeutics $13.61 / +0.355 (+2.68%) 05/09/22 BioXcel Therapeutics reports Q1 EPS ($1.12), consensus ($1.15) 03/10/22 BioXcel Therapeutics reports Q4 EPS (93c), consensus ($1.10) 23 Jun BTAI BioXcel Therapeutics $13.61 / +0.355 (+2.68%) 04/06/22 Fly Intel: Pre-market Movers

Recommendations	Xencor price target lowered to $42 from $66 at Piper Sandler » 06:18 05/23/22 05/23 06:18 05/23/22 06:18 XNCR Xencor $23.53 / +0.52 (+2.26%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events XNCR Xencor $23.53 / +0.52 (+2.26%) 05/05/22 Xencor to end 2022 with $500M-$550M in cash 04/08/22 Xencor presents data from multiple preclinical XmAb cytokine programs at AACR 02/23/22 Xencor sees ending 2021 with $500M-$550M in cash, cash equivalents 12/12/21 Xencor presents data from Phase 1 dose-escalation study of plamotamab XNCR Xencor $23.53 / +0.52 (+2.26%) 05/06/22 Piper Sandler Xencor price target lowered to $66 from $71 at Piper Sandler 02/24/22 H.C. Wainwright Xencor price target lowered to $55 from $61 at H.C. Wainwright 02/10/22 BMO Capital Xencor initiated with an Outperform at BMO Capital 01/03/22 Piper Sandler Xencor named a top pick for 2022 at Piper Sandler XNCR Xencor $23.53 / +0.52 (+2.26%) 05/05/22 Xencor reports Q1 EPS 39c, consensus (60c) 02/23/22 Xencor reports Q4 EPS $1.21, consensus (10c) 06/23/22 Xencor, Inc.
Recommendations	Sutro Biopharma price target lowered to $14 from $29 at Piper Sandler » 06:18 05/23/22 05/23 06:18 05/23/22 06:18 STRO Sutro Biopharma $4.66 / +0.12 (+2.64%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events STRO Sutro Biopharma $4.66 / +0.12 (+2.64%) 04/08/22 Sutro Biopharma presents nonclinical data for STRO-002 at AACR meeting 01/05/22 Sutro Biopharma reports interim data from dose-expansion cohort of STRO-002 12/27/21 Sutro, Talsy enter exclusive license agreement for STRO-002 in Greater China STRO Sutro Biopharma $4.66 / +0.12 (+2.64%) 05/11/22 H.C. Wainwright Sutro Biopharma price target lowered to $30 from $35 at H.C. Wainwright 05/10/22 Wedbush Sutro Biopharma price target lowered to $20 from $30 at Wedbush 03/07/22 JMP Securities Sutro Biopharma price target lowered to $20 from $28 at JMP Securities 01/06/22 Wedbush Sutro Biopharma price target lowered to $30 from $37 at Wedbush STRO Sutro Biopharma $4.66 / +0.12 (+2.64%) 05/09/22 Sutro Biopharma reports Q1 EPS (84c), consensus (76c) 02/28/22 Sutro Biopharma reports FY21 EPS ($2.29), consensus ($2.16) STRO Sutro Biopharma $4.66 / +0.12 (+2.64%) 01/06/22 Wall Street in Fives - Must Read Lists for Thursday 01/06/22 Wall Street in Fives - Must Read Lists at Midday 01/05/22 Fly Intel: After-Hours Movers 12/27/21 Fly Intel: Pre-market Movers 06/06/22 Sutro Biopharma, Inc.
Recommendations	Omega Therapeutics price target lowered to $7 from $30 at Piper Sandler » 06:18 05/23/22 05/23 06:18 05/23/22 06:18 OMGA Omega Therapeutics $2.70 / -0.085 (-3.05%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options OMGA Omega Therapeutics $2.70 / -0.085 (-3.05%) 04/29/22 Omega Therapeutics names Joshua Reed as CFO, effective May 23 04/08/22 Omega Therapeutics: OTX-2002 supresses c-Myc gene expression in trial 03/30/22 Omega Therapeutics appoints CHRO and Chief Legal and Administrative Officer 01/10/22 Omega Therapeutics names Yan Moore, M.D., as Chief Medical Officer OMGA Omega Therapeutics $2.70 / -0.085 (-3.05%) 08/24/21 Fly Intel: Top five analyst initiations 08/24/21 Wedbush Wedbush bullish on Omega Therapeutics, initiates with an Outperform 08/24/21 Jefferies Omega Therapeutics initiated with a Buy at Jefferies 08/24/21 Wedbush Omega Therapeutics initiated with an Outperform at Wedbush OMGA Omega Therapeutics $2.70 / -0.085 (-3.05%) 03/10/22 Omega Therapeutics reports Q4 EPS (44c), consensus (53c) 30 Jul OMGA Omega Therapeutics $2.70 / -0.085 (-3.05%) 03/10/22 Fly Intel: Pre-market Movers 06/08/22 Omega Therapeutics, Inc. OMGA Omega Therapeutics $2.70 / -0.085 (-3.05%) 03/09/22 Twenty new option listings and one option delisting on March 9th
Recommendations	NextCure price target lowered to $13 from $21 at Piper Sandler » 06:17 05/23/22 05/23 06:17 05/23/22 06:17 NXTC NextCure $3.80 / +0.125 (+3.41%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Events NXTC NextCure $3.80 / +0.125 (+3.41%) 04/19/22 NextCure, NCI announce preclinical data in Journal of Clinical Investigation 12/13/21 NextCure, collaborators provide data on targets in development at ASH meeting NXTC NextCure $3.80 / +0.125 (+3.41%) 03/01/22 Ladenburg NextCure initiated with Buy, $16 price target at Ladenburg 03/01/22 Ladenburg NextCure initiated with a Buy at Ladenburg 11/05/21 Piper Sandler NextCure's Phase II NC318 study continuing weekly dosing, says Piper Sandler 08/08/21 Piper Sandler NextCure price target lowered to $21 from $26 at Piper Sandler 05/25/22 NextCure 06/23/22 NextCure, Inc.
Hot Stocks	JPMorgan sees 12.5%-13% CET1 ratio at 1Q24 » 06:17 05/23/22 05/23 06:17 05/23/22 06:17 JPM JPMorgan $117.34 / -0.945 (-0.80%) The company's ROTCE… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JPM JPMorgan $117.34 / -0.945 (-0.80%) 06:17 Today JPMorgan sees FY22 NII excluding Markets $56B+ vs. previous $53B+ view 05/13/22 Soros buys Lucid, exits GM in Q1 05/10/22 JPMorgan launches new data plaform for the buy-side 05/10/22 Peloton to borrow $750M in 5-year term debt, says CEO JPM JPMorgan $117.34 / -0.945 (-0.80%) 05/13/22 Jefferies JPMorgan price target lowered to $125 from $141 at Jefferies 05/03/22 Oppenheimer Oppenheimer upgrades JPMorgan to Outperform on recent share weakness 05/03/22 Oppenheimer JPMorgan upgraded to Outperform from Perform at Oppenheimer 04/14/22 Argus JPMorgan price target lowered to $155 from $177 at Argus JPM JPMorgan $117.34 / -0.945 (-0.80%) 04/13/22 JPMorgan reports Q1 EPS $2.63, consensus $2.69 04/12/22 Notable companies reporting before tomorrow's open 04/12/22 Notable companies reporting before tomorrow's open 01/14/22 JPMorgan reports Q4 EPS $3.33, consensus $3.01 JPM JPMorgan $117.34 / -0.945 (-0.80%) 05/19/22 BlackRock, JPMorgan tell Texas they're not boycotting energy firms, Reuters says 05/18/22 JPMorgan investors reject Dimon's $50M bonus, WSJ reports 05/12/22 Instacart listing could happen as soon as this year, Bloomberg reports 05/08/22 Ford to sell 8M shares of Rivian with lockup expiring, CNBC reports JPM JPMorgan $117.34 / -0.945 (-0.80%) 05/14/22 Opening Day: Fracking company ProFrac comes public in downsized IPO 05/09/22 What You Missed This Week in EVs and Clean Energy 05/03/22 What You Missed On Wall Street On Tuesday 05/03/22 What You Missed On Wall Street This Morning 00:00 Today 50th Annual Global Technology, Media & Communications Conference 07/14/22 JPMorgan - JPM 08:00 Today JPMorgan JPM JPMorgan $117.34 / -0.945 (-0.80%) 04/14/22 Notable open interest changes for April 14th 02/08/22 Early notable gainers among liquid option names on February 8th 01/14/22 Unusually active option classes on open January 14th 01/04/22 Unusually active option classes on open January 4th

Recommendations	Seres Therapeutics price target lowered to $7 from $32 at Piper Sandler » 06:17 05/23/22 05/23 06:17 05/23/22 06:17 MCRB Seres Therapeutics $3.57 / +0.15 (+4.39%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events MCRB Seres Therapeutics $3.57 / +0.15 (+4.39%) 05/22/22 Seres Therapeutics presents Phase 3 results of SER-109 for rCDI 05/10/22 Seres Therapeutics to present data on SER-108 at DDW meeting 04/06/22 Seres Therapeutics discontinues SER-301 study in ulcerative colitis 02/08/22 Seres Therapeutics appoints Paula Cloghessy as Chief People Officer MCRB Seres Therapeutics $3.57 / +0.15 (+4.39%) 04/06/22 H.C. Wainwright Seres study discontinuation does not impact valuation, says H.C. Wainwright 08/03/21 Oppenheimer Seres Therapeutics price target lowered to $16 from $18 at Oppenheimer 07/23/21 Fly Intel: Top five analyst downgrades 07/23/21 Oppenheimer Seres Therapeutics price target lowered to $18 from $36 at Oppenheimer MCRB Seres Therapeutics $3.57 / +0.15 (+4.39%) 05/04/22 Seres Therapeutics reports Q1 EPS (61c), consensus (52c) 03/01/22 Seres Therapeutics reports FY22 EPS (72c) versus ($1.12) last year 06/22/22 Seres Therapeutics, Inc.
Recommendations	Kymera Therapeutics price target lowered to $43 from $91 at Piper Sandler » 06:17 05/23/22 05/23 06:17 05/23/22 06:17 KYMR Kymera Therapeutics $14.80 / -0.085 (-0.57%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events KYMR Kymera Therapeutics $14.80 / -0.085 (-0.57%) 05/20/22 Kymera presents preclinical data on IRAK4 degrader KT-474 at SID meeting 05/05/22 Kymera Therapeutics presents preclinical results on STAT3 degradation 05/03/22 Kymera Therapeutics expects cash, cash equivalents to fund operations into 2025 05/03/22 Kymera Therapeutics announces upcoming expected milestones KYMR Kymera Therapeutics $14.80 / -0.085 (-0.57%) 05/04/22 B. Riley Kymera Therapeutics price target lowered to $50 from $67 at B. Riley 04/28/22 Credit Suisse Kymera Therapeutics initiated with an Outperform at Credit Suisse 03/10/22 JPMorgan Kymera Therapeutics initiated with a Neutral at JPMorgan 02/10/22 Wells Fargo Wells Fargo bullish on Kymera Therapeutics, initiates with an Overweight KYMR Kymera Therapeutics $14.80 / -0.085 (-0.57%) 05/03/22 Kymera Therapeutics reports Q1 EPS (71c), consensus (66c) 02/24/22 Kymera Therapeutics reports Q4 EPS (66c), consensus (64c) 01 Jul KYMR Kymera Therapeutics $14.80 / -0.085 (-0.57%) 05/06/22 Proven algorithm says sell these stocks now 04/22/22 Get Out Of These Stocks Now, POWR Ratings Algorithm Says 03/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/07/22 2022 Wells Fargo Healthcare Conference 06/15/22 Kymera Therapeutics, Inc.
Recommendations	Kronos Bio price target lowered to $13 from $30 at Piper Sandler » 06:17 05/23/22 05/23 06:17 05/23/22 06:17 KRON Kronos Bio $3.81 / +0.255 (+7.17%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events KRON Kronos Bio $3.81 / +0.255 (+7.17%) 04/08/22 Kronos Bio data show potential of KB-0742 in breast, lung, ovarian cancers 12/06/21 Kronos Bio first patient dosed in AGILITY Phase 3 trial of entospletinib 11/29/21 Kronos Bio announces data from ongoing Phase 1/2 trial of KB-0742 KRON Kronos Bio $3.81 / +0.255 (+7.17%) 02/27/22 Piper Sandler Kronos Bio price target lowered to $30 from $50 at Piper Sandler 10/19/21 Cowen Kronos Bio assumed with an Outperform at Cowen 06/24/21 H.C. Wainwright Kronos Bio initiated with a Buy at H.C. Wainwright 06/11/21 Piper Sandler Kronos Bio transferred with Overweight, $50 target at Piper Sandler KRON Kronos Bio $3.81 / +0.255 (+7.17%) 05/04/22 Kronos Bio reports Q1 EPS (65c), consensus (66c) 02/24/22 Kronos Bio reports Q4 EPS ($1.13), consensus ($1.10) 06/22/22 Kronos Bio, Inc.
Recommendations	Jounce Therapeutics price target lowered to $9 from $17 at Piper Sandler » 06:17 05/23/22 05/23 06:17 05/23/22 06:17 JNCE Jounce Therapeutics $4.69 / +0.16 (+3.53%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events JNCE Jounce Therapeutics $4.69 / +0.16 (+3.53%) 05/05/22 Jounce Therapeutics sees cash, cash equivalents funding operations into Q3 2023 JNCE Jounce Therapeutics $4.69 / +0.16 (+3.53%) 05/12/22 Roth Capital Jounce Therapeutics recent pullback overdone, says Roth Capital 05/11/22 Baird Jounce Therapeutics downgraded on JTX-8064 concerns at Baird 05/11/22 Baird Jounce Therapeutics downgraded to Neutral from Outperform at Baird 05/06/22 Raymond James Jounce Therapeutics upgraded to Strong Buy from Outperform at Raymond James JNCE Jounce Therapeutics $4.69 / +0.16 (+3.53%) 05/05/22 Jounce Therapeutics reports Q1 EPS (72c), consensus (57c) 03/02/22 Jounce Therapeutics sees cash, cash equivalents funding operations into Q3 2023 03/02/22 Jounce Therapeutics reports Q4 EPS (59c), consensus (32c) JNCE Jounce Therapeutics $4.69 / +0.16 (+3.53%) 05/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/24/22 Jounce Therapeutics, Inc.
Recommendations	Infinity Pharmaceuticals price target lowered to $3 from $4 at Piper Sandler » 06:17 05/23/22 05/23 06:17 05/23/22 06:17 INFI Infinity Pharmaceuticals / + Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events INFI Infinity Pharmaceuticals / + 01/05/22 Infinity outlines strategy, sees FY22 net loss $45M-$55M 12/10/21 Infinity Pharmaceuticals presents updated data from MARIO-3 study INFI Infinity Pharmaceuticals / + 03/31/22 Truist Infinity Pharmaceuticals price target lowered to $4 from $12 at Truist 03/29/22 Piper Sandler Infinity Pharmaceuticals price target lowered to $4 from $8 at Piper Sandler 01/24/22 B. Riley Infinity Pharmaceuticals price target lowered to $5 from $7 at B. Riley 12/16/21 B. Riley Infinity Pharmaceuticals price target raised to $7 from $4 at B. Riley INFI Infinity Pharmaceuticals / + 05/03/22 Infinity Pharmaceuticals reports Q1 EPS (14c), consensus (13c) 03/29/22 Infinity Pharmaceuticals reports FY21 EPS (53c), consensus (53c) 06/16/22 Infinity Pharmaceuticals Inc.

Events

Earnings calls, analyst events, roadshows and more

CAAS
Today at 08:00

China Automotive - CAAS Conference Calls
XPEV
Today at 08:00

XPeng - XPEV Conference Calls
NIU
Today at 08:00

Niu Technologies - NIU Conference Calls
CSTE
Today at 08:00

Caesarstone Firm Sponsored Meetings

Virtual Meeting
JPM
Today at 08:00

JPMorgan Firm Sponsored Meetings

Virtual Meeting
Today at 08:30

Chicago Fed National Activity Index--3 Month Moving Average: April 2022 Government Event
Today at 08:30

Chicago Fed National Activity Index: April 2022 Government Event
RSLS
Today at 08:30

ReShape Lifesciences - RSLS Conference Calls
AVPT
Today at 09:00

AvePoint Firm Sponsored Meetings

Virtual Meeting
GILT
Today at 09:30

Gilat Satellite - GILT Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Orbcomm downgraded to Hold from Buy at Craig-Hallum

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access